首页> 美国卫生研究院文献>Journal of Clinical Medicine >Toward Engineering the Mannose 6-Phosphate Elaboration Pathway in Plants for Enzyme Replacement Therapy of Lysosomal Storage Disorders
【2h】

Toward Engineering the Mannose 6-Phosphate Elaboration Pathway in Plants for Enzyme Replacement Therapy of Lysosomal Storage Disorders

机译:致力于工程化植物中的甘露糖6-磷酸精细化途径以进行溶酶体贮积症的酶替代治疗。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mucopolysaccharidosis (MPS) I is a severe lysosomal storage disease caused by α-L-iduronidase (IDUA) deficiency, which results in accumulation of non-degraded glycosaminoglycans in lysosomes. Costly enzyme replacement therapy (ERT) is the conventional treatment for MPS I. Toward producing a more cost-effective and safe alternative to the commercial mammalian cell-based production systems, we have produced recombinant human IDUA in seeds of an mutant to generate the enzyme in a biologically active and non-immunogenic form containing predominantly high mannose N-linked glycans. Recombinant enzyme in ERT is generally thought to require a mannose 6-phosphate (M6P) targeting signal for endocytosis into patient cells and for intracellular delivery to the lysosome. Toward effecting phosphorylation, the human M6P elaboration machinery was successfully co-expressed along with the recombinant human IDUA using a single multi-gene construct. Uptake studies using purified putative M6P-IDUA generated on cultured MPS I primary fibroblasts indicated that the endocytosed recombinant lysosomal enzyme led to substantial reduction of glycosaminoglycans. However, the efficiency of the putative M6P-IDUA in reducing glycosaminoglycan storage was comparable with the efficiency of the purified plant mannose-terminated IDUA, suggesting a poor M6P-elaboration by the expressed machinery. Although the M6P-tagging process efficiency would need to be improved, an exciting outcome of our work was that the plant-derived mannose-terminated IDUA yielded results comparable to those obtained with the commercial IDUA (Aldurazyme (Sanofi, Paris, France)), and a significant amount of the plant-IDUA is trafficked by a M6P receptor-independent pathway. Thus, a plant-based platform for generating lysosomal hydrolases may represent an alternative and cost-effective strategy to the conventional ERT, without the requirement for additional processing to create the M6P motif.
机译:粘多糖贮积病(MPS)I是一种严重的溶酶体贮积病,由α-L-艾杜糖苷酸酶(IDUA)缺乏引起,导致未降解的糖胺聚糖在溶酶体中积累。昂贵的酶替代疗法(ERT)是MPS I的常规治疗方法。为了生产一种成本效益更高,更安全的替代商业哺乳动物细胞生产系统的替代品,我们在突变体的种子中生产了重组人IDUA以产生该酶以生物活性和非免疫原性形式存在,主要包含高甘露糖N-连接的聚糖。通常认为ERT中的重组酶需要将6-磷酸甘露糖(M6P)靶向信号才能内吞进入患者细胞并向胞内递送至溶酶体。为了实现磷酸化,使用单个多基因构建体将人M6P精细加工机制与重组人IDUA成功地共表达。使用在培养的MPS I初级成纤维细胞上产生的纯化推定的M6P-IDUA进行的摄取研究表明,内吞的重组溶酶体酶导致糖胺聚糖的大量减少。但是,推定的M6P-IDUA减少糖胺聚糖存储的效率与纯化的植物甘露糖末端的IDUA的效率相当,表明所表达的机器对M6P的修饰较差。尽管M6P标记过程的效率需要提高,但我们工作的令人兴奋的结果是,植物来源的甘露糖末端的IDUA产生的结果可与商业IDUA(Aldurazyme(Sanofi,巴黎,法国))获得的结果相媲美,并且大量的植物IDUA通过M6P受体非依赖性途径转运。因此,用于产生溶酶体水解酶的基于植物的平台可以代表常规ERT的替代和成本有效的策略,而不需要额外的处理来产生M6P基序。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号